Agendia and Genecast Biotechnology Partner to Launch MammaPrint and BluePrint in China
For the first time, early-stage breast cancer patients and their Read More
US Oncology Research Joins Agendia’s FLEX Big Data Initiative, Accelerating Diagnostic Discoveries in Breast Cancer and Enabling Precision Oncology
Dataset of up to 10,000 full genome profiles matched with Read More
An Update on Agendia’s Precision Oncology Achievements in Breast Cancer
As we close out the first half of 2018, I’d Read More
Agendia Secures $35 Million Investment from Funds Managed by Athyrium Capital Management to Support Expanded Commercial Footprint in Rapidly Growing Markets and New Research Collaborations
IRVINE, CA and AMSTERDAM, NETHERLANDS – 25 July 2018 – Read More
An Open Letter to Women With Early-Stage Breast Cancer and Their Healthcare Teams:
One of the biggest questions that early-stage breast cancer patients Read More
Key Studies at the American Society of Clinical Oncology (ASCO) Annual Meeting Demonstrate MammaPrint and BluePrint’s Utility in Personalizing Neoadjuvant Treatment Approaches for Early-Stage Breast Cancer Patients
New data from the I-SPY 2 trial highlights residual cancer Read More
Agendia and Angsana to Provide Breast Cancer Risk-of-Recurrence Testing with MammaPrint and BluePrint to Patients in Southeast Asia
Partnership will enable women in Singapore, Malaysia, Vietnam, Brunei and Read More
Agendia’s MammaPrint and BluePrint Breast Cancer Tests Selected by Unicancer for French Patients
IRVINE, CA, AMSTERDAM, NETHERLANDS – 15 May 2018 – Agendia, Read More
Agendia’s MammaPrint Receives Positive Coverage Decisions from Three Major Private Healthcare Insurers
Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update Read More
Agendia Announces CE Mark for NGS-Based MammaPrint BluePrint Kit Enhancing Access to Personalized Treatment for Breast Cancer Patients in Europe
IRVINE, CA, AMSTERDAM, NETHERLANDS – 21 March 2018 – Agendia, Read More
